Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2019 Jun;67(6):969-970.
doi: 10.4103/ijo.IJO_1220_17.

Commentary: Antivascular endothelial growth factor and retinopathy of prematurity

Ajay Indur Dudani  1 , Anupam Dudani  1 , Krish Dudani  1
Affiliations
Comment

Commentary: Antivascular endothelial growth factor and retinopathy of prematurity

Ajay Indur Dudani et al. Indian J Ophthalmol. 2019 Jun.
No abstract available

PubMed Disclaimer

Conflict of interest statement

None

Comment on

References

    1. Jain P, Sheth J, Anantharaman G, Gopalakrishnan M. Real-world evidence of safety profile of intravitreal bevacizumab (Avastin) in an Indian scenario. Indian J Ophthalmol. 2017;65:596–602. - PMC - PubMed
    1. Mintz-Hittner HA, Kennedy KA, Chuang AZ BEAT-ROP Cooperative Group. Efficacy of intravitreal bevacizumab for stage 3+retinopathy of prematurity. N Engl J Med. 2011;364:603–15. - PMC - PubMed
    1. Jalali S, Balakrishnan D, Zeynalova Z, Padhi TR, Rani PK. Serious adverse events and visual outcomes of rescue therapy using adjunct bevacizumab to laser and surgery for retinopathy of prematurity. The Indian twin cities retinopathy of prematurity screening database report number 5. Arch Dis Child Fetal Neonatal Ed. 2013;98:F327–33. - PubMed
    1. Hwang CK, Hubbard GB, Hutchinson AK, Lambert SR. Outcomes after intravitreal bevacizumab versus laser photocoagulation for retinopathy of prematurity: A 5-year retrospective analysis. Ophthalmology. 2015;122:1008–15. - PMC - PubMed
    1. Sankar MJ, Sankar J, Chandra P. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity. Cochrane Database Syst Rev. 2018;1:CD009734. - PMC - PubMed